Rheumatoid Arthritis News

Baseline rituximab or JAK inhibitor use for rheumatoid arthritis was associated with worse COVID-19 severity, compared with TNF-inhibitor use, according to a speaker at the EULAR 2021 Congress.

Findings from the Live Yes! INSIGHTS survey from the Arthritis Foundation showed that out of some 40,000 patient responses, 100% reported experiencing some kind of pain within the last 7 days.

Although the seroprevalence of SARS-CoV-2 in patients with immune-mediated inflammatory diseases is comparable to the general population, increased systemic inflammation among these patients is linked to symptomatic COVID-19, according to researchers.

The U.S. Supreme Court has denied a petition from Novartis’ Sandoz to review an earlier U.S. appeals court ruling in favor of Amgen’s etanercept against etanercept-szzs, effectively blocking the biosimilar from entering the U.S. market.

Cannabis, cannabis-derived products and synthetic cannabinoids may slightly decrease rheumatoid arthritis disease activity, according to a meta-analysis published in the Journal of Clinical Rheumatology.

Proactive therapeutic drug monitoring vs. standard therapy did not significantly improve clinical remission rates over 30 weeks in patients with immune-mediated inflammatory diseases initiating Remicade therapy, according to study results.

Studies that feature work participation as an outcome in patients with inflammatory arthritis should identify key contextual factors — such as job type or social security system — upfront, according to new “points to consider” from EULAR.

The FDA has issued a warning letter to an online pharmacy for allegedly selling unapproved and misbranded drugs, including hydroxychloroquine and chloroquine, for the treatment of COVID-19, lupus, rheumatoid arthritis and other diseases.

Clinicians should be aware of racial and cultural differences in the perception of health care and tailor their approach accordingly, and reduce potential health care disparities, noted a speaker at the 2021 Interdisciplinary Autoimmune Summit.

Janus kinase inhibitors “may prove useful” in a wider range of immune-mediated inflammatory diseases, including refractory cutaneous dermatomyositis, chronic plaque psoriasis and other conditions, according to a speaker here.